ClinicalTrials.gg
CompletedNCT02115633Updated Oct 30, 2018Results posted

A Wearable "Balance Booster" - Stepping Closer to the Market

An interventional study of Walkasins ON and Walkasins OFF in Distorted; Balance, Sensation Disorders and Peripheral Neuropathy, sponsored by RxFunction Inc.. Completed. Per ClinicalTrials.gov, last updated 2018-10-30.

Sponsored by RxFunction Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Sex
All
01

Study summary

The overall goal of this project is to continue development and commercialization of a Wearable Sensory Prosthesis termed Walkasins. The device measures foot pressure through a thin sole insert, developed under National Institute on Aging (NIA) Small Business Innovation Research (SBIR) Phase I funding, and displays pressure information through a vibrotactile feedback array, placed around the lower leg, to help improve balance function. The device can replace lost foot pressure sensation in individuals with peripheral neuropathy who have balance problems.

Read the detailed description

Our specific aims are to:

  1. Revise and finalize design of Walkasins® based on accomplishments, user input, as well as reviewer criticism from our Phase 1 grant and manufacture 200 units of the device for clinical testing.

    Milestone 1: 200 units manufactured and ready for clinical testing under Aim 2. This goal is accomplished.

  2. Investigate effects of using Walkasins on clinical outcomes related to gait, balance function and associated fall risk in a population of patients with sensory peripheral neuropathy and balance problems.

Hypotheses 1A-B: Patients who are trained to use Walkasins programmed to display relevant balance cues will attain higher gait speed and Functional Gait Assessment when compared to a matched cohort not using Walkasins.

Milestone 2: Data collection to assess clinical utility and safety of the Walkasins on patients briefly trained to use the device has been completed.

02

Conditions studied

  • Distorted; Balance
  • Sensation Disorders
  • Peripheral Neuropathy
  • Neuropathy
03

In context

Sensation Disorders

87 studies on the registry are indexed under Sensation Disorders; 23 are open to participants now.

This study's enrollment of 31 is below the median of 40 across 56 interventional studies indexed under Sensation Disorders.

Browse Sensation Disorders studies →

Lead sponsor

RxFunction Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of any age diagnosed with Peripheral Neuropathy and who experience balance problems.
  • Ability to perceive the Walkasins vibration feedback, understand and physically act on the vibration feedback.

Exclusion criteria

Exclusion Criteria:

  • Vibration to the skin is by physician

    • Use of ankle foot orthotic that prevents attachment of Walkasins device
  • Foot size smaller than Woman's 5 or larger than Men's 13
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Walkasins ON then OFF

    Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.

    Device: Walkasins ON · Device: Walkasins OFF

  • Experimental
    Walkasins OFF then ON

    Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.

    Device: Walkasins ON · Device: Walkasins OFF

Interventions

  • DeviceWalkasins ON

    Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.

  • DeviceWalkasins OFF

    Subjects will be wearing a device that is turned off.

06

What researchers measure

Primary outcomes

  1. Functional Gait Assessment (FGA)

    The Functional Gait Assessment (FGA) is a reliable and valid measure of gait function related to postural stability and has been shown to be effective in classifying fall risk in older adults and predicting unexplained falls in community-dwelling older adults (Wrisley, Marchetti et al. 2004; Wrisley and Kumar 2010). It has also been validated in stroke survivors (Lin, Hsu et al. 2010) and patients with Parkinson's disease (Leddy, Crowner et al. 2011) and has less flooring and ceiling effect than the Dynamic Gait Index (Lin, Hsu et al. 2010). The FGA includes a 10-item scale; each item is scored from 0 to 3 (3=normal, 2=mild impairment, 1=moderate impairment, 0=severe impairment). The maximum score is 30; minimum score, 0. Higher scores represent a better outcome. To be included in the count of participants, subjects' FGA scores needed to improve more than 4 points, which is the Minimally Clinically Important Difference (MCID) (Beninato et al. 2014).

    Time frame: During one test session < 3 hours

Secondary outcomes

  1. Four-Stage Balance Test >30s

    The 4-Stage Balance Test is part of the STEADI protocol recommended by the Centers for Disease Control and Prevention (CDC) to assess fall-risk in elderly individuals. It includes four gradually more challenging postures the subject performs; 1) Stand with feet side by side; 2) Stand with feet in semi-tandem stance; 3) Stand with feet in tandem stance; 4) Stand on one leg. Subjects pass if they can hold the stance for 10 seconds and then move on to the next stance. A fail during tasks 1, 2, or 3 indicates a high risk of falling, i.e., a total performance time of less than 30 seconds.

    Time frame: The assessment requires holding each stance for 10 seconds for a total of 40 seconds to pass.

  2. 10-Meter (10M) Walk Test (Measure of Gait Speed)--Number of Participants With Improvement to Normal Gait Speed

    The 10m-walk is routinely done in rehabilitation and has excellent reliability in chronic stroke patients. In addition, gait speed has been found to be an important predictor of survival in older adults (Hardy, Perera et al. 2006), further emphasizing its importance as a clinical outcomes measure. Gait speed (10-meter walk, timing only the middle 6 meters to allow for acceleration and deceleration) was assessed by instructing subjects to walk at their normal speed. A difference of 0.10m/sec is defined as the Minimally Clinical Important Difference (MCID) (Perera, Mody et al. 2006). Lower scores (# of seconds) on this measure indicate a better outcome. To be included in the count of participants, subjects' times on the 10M Walk Test needed to improve by more than 0.10m/sec, the MCID.

    Time frame: During one test session < 3 hours

  3. Activities-Specific Balance Confidence Scale (ABC)

    Powell and Myers (1995) developed the Activities-specific Balance Confidence (ABC) Scale to detect levels of balance confidence in elderly persons. The ABC scale is a one-page questionnaire that asks questions about balance confidence when performing 16 different tasks. The items are rated on a scale of 0 to 100; a score of 0 indicates no confidence and a score of 100 indicates complete confidence when performing the task. The overall score is calculated by adding the individual items then dividing by the total number of items (16). The higher the score, the greater the person's balance confidence; thus, higher scores indicate that subjects are more confident of their balance. The ABC Scale was assessed only at baseline to document the level of balance confidence the subjects had before beginning the study intervention.

    Time frame: Measure was administered only at baseline during one test session <3 hours.

07

Results

Posted Oct 30, 2018
Limitations and caveats
Study limitations included the following: * The study was not blinded. * The study involved a small group consisting of males only. * The study was only short-term (\<3 hours).

Participant flow

Thirty-one male community-dwelling veterans, ages 56-84, who experienced sensory peripheral neuropathy and balance problems, participated in the trial.

Participant flow — Overall Study
MilestoneWalkasins On Then OffWalkasins Off Then On
Started1516
Completed1516
Not completed00

Outcome measures

PrimaryFunctional Gait Assessment (FGA)

The Functional Gait Assessment (FGA) is a reliable and valid measure of gait function related to postural stability and has been shown to be effective in classifying fall risk in older adults and predicting unexplained falls in community-dwelling older adults (Wrisley, Marchetti et al. 2004; Wrisley and Kumar 2010). It has also been validated in stroke survivors (Lin, Hsu et al. 2010) and patients with Parkinson's disease (Leddy, Crowner et al. 2011) and has less flooring and ceiling effect than the Dynamic Gait Index (Lin, Hsu et al. 2010). The FGA includes a 10-item scale; each item is scored from 0 to 3 (3=normal, 2=mild impairment, 1=moderate impairment, 0=severe impairment). The maximum score is 30; minimum score, 0. Higher scores represent a better outcome. To be included in the count of participants, subjects' FGA scores needed to improve more than 4 points, which is the Minimally Clinically Important Difference (MCID) (Beninato et al. 2014).

Time frame:
During one test session < 3 hours
Reported as:
Count of participants · Participants
Functional Gait Assessment (FGA)
ParticipantsWalkasins ONWalkasins OFF
Functional Gait Assessment (FGA)177
SecondaryFour-Stage Balance Test >30s

The 4-Stage Balance Test is part of the STEADI protocol recommended by the Centers for Disease Control and Prevention (CDC) to assess fall-risk in elderly individuals. It includes four gradually more challenging postures the subject performs; 1) Stand with feet side by side; 2) Stand with feet in semi-tandem stance; 3) Stand with feet in tandem stance; 4) Stand on one leg. Subjects pass if they can hold the stance for 10 seconds and then move on to the next stance. A fail during tasks 1, 2, or 3 indicates a high risk of falling, i.e., a total performance time of less than 30 seconds.

Time frame:
The assessment requires holding each stance for 10 seconds for a total of 40 seconds to pass.
Reported as:
Mean · number of seconds stances held
Four-Stage Balance Test >30s
number of seconds stances heldWalkasins ONWalkasins OFF
Four-Stage Balance Test >30s27.5 ± 7.425.6 ± 8.3
Secondary10-Meter (10M) Walk Test (Measure of Gait Speed)--Number of Participants With Improvement to Normal Gait Speed

The 10m-walk is routinely done in rehabilitation and has excellent reliability in chronic stroke patients. In addition, gait speed has been found to be an important predictor of survival in older adults (Hardy, Perera et al. 2006), further emphasizing its importance as a clinical outcomes measure. Gait speed (10-meter walk, timing only the middle 6 meters to allow for acceleration and deceleration) was assessed by instructing subjects to walk at their normal speed. A difference of 0.10m/sec is defined as the Minimally Clinical Important Difference (MCID) (Perera, Mody et al. 2006). Lower scores (# of seconds) on this measure indicate a better outcome. To be included in the count of participants, subjects' times on the 10M Walk Test needed to improve by more than 0.10m/sec, the MCID.

Time frame:
During one test session < 3 hours
Reported as:
Count of participants · Participants
10-Meter (10M) Walk Test (Measure of Gait Speed)--Number of Participants With Improvement to Normal Gait Speed
ParticipantsWalkasins ONWalkasins OFF
10-Meter (10M) Walk Test (Measure of Gait Speed)--Number of Participants With Improvement to Normal Gait Speed85
SecondaryActivities-Specific Balance Confidence Scale (ABC)

Powell and Myers (1995) developed the Activities-specific Balance Confidence (ABC) Scale to detect levels of balance confidence in elderly persons. The ABC scale is a one-page questionnaire that asks questions about balance confidence when performing 16 different tasks. The items are rated on a scale of 0 to 100; a score of 0 indicates no confidence and a score of 100 indicates complete confidence when performing the task. The overall score is calculated by adding the individual items then dividing by the total number of items (16). The higher the score, the greater the person's balance confidence; thus, higher scores indicate that subjects are more confident of their balance. The ABC Scale was assessed only at baseline to document the level of balance confidence the subjects had before beginning the study intervention.

Time frame:
Measure was administered only at baseline during one test session <3 hours.
Reported as:
Mean · score on a scale of 0-100
Activities-Specific Balance Confidence Scale (ABC)
score on a scale of 0-100Walkasins ON Then OFFWalkasins OFF
Activities-Specific Balance Confidence Scale (ABC)59.6 ± 19.364.7 ± 17.3

Adverse events

Collected over During a 3-hour testing period. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Walkasins ON Then OFF0/15 (0%)0/15 (0%)0/15 (0%)
Walkasins OFF Then ON0/16 (0%)0/16 (0%)0/16 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Walkasins OnWalkasins OffTotal
Mean71.6 ± 7.171.6 ± 6.271.6 ± 6.65
Sex: Female, Male
Sex: Female, Male(Participants)Walkasins OnWalkasins OffTotal
Female000
Male151631
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Walkasins OnWalkasins OffTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Walkasins OnWalkasins OffTotal
United States151631
Functional Gait Assessment (FGA) Score
Functional Gait Assessment (FGA) Score(units on a scale)Walkasins OnWalkasins OffTotal
Mean15.0 ± 4.515.4 ± 5.215.2 ± 4.9
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Beninato M, Fernandes A, Plummer LS. Minimal clinically important difference of the functional gait assessment in older adults. Phys Ther. 2014 Nov;94(11):1594-603. doi: 10.2522/ptj.20130596. Epub 2014 Jun 19. PubMed 24947198 ↗
  • Hardy SE, Perera S, Roumani YF, Chandler JM, Studenski SA. Improvement in usual gait speed predicts better survival in older adults. J Am Geriatr Soc. 2007 Nov;55(11):1727-34. doi: 10.1111/j.1532-5415.2007.01413.x. Epub 2007 Oct 3. PubMed 17916121 ↗
  • Leddy AL, Crowner BE, Earhart GM. Functional gait assessment and balance evaluation system test: reliability, validity, sensitivity, and specificity for identifying individuals with Parkinson disease who fall. Phys Ther. 2011 Jan;91(1):102-13. doi: 10.2522/ptj.20100113. Epub 2010 Nov 11. PubMed 21071506 ↗
  • Lin JH, Hsu MJ, Hsu HW, Wu HC, Hsieh CL. Psychometric comparisons of 3 functional ambulation measures for patients with stroke. Stroke. 2010 Sep;41(9):2021-5. doi: 10.1161/STROKEAHA.110.589739. Epub 2010 Jul 29. PubMed 20671244 ↗
  • Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006 May;54(5):743-9. doi: 10.1111/j.1532-5415.2006.00701.x. PubMed 16696738 ↗
  • Powell LE, Myers AM. The Activities-specific Balance Confidence (ABC) Scale. J Gerontol A Biol Sci Med Sci. 1995 Jan;50A(1):M28-34. doi: 10.1093/gerona/50a.1.m28. PubMed 7814786 ↗
  • Wrisley DM, Kumar NA. Functional gait assessment: concurrent, discriminative, and predictive validity in community-dwelling older adults. Phys Ther. 2010 May;90(5):761-73. doi: 10.2522/ptj.20090069. Epub 2010 Apr 1. PubMed 20360052 ↗
  • Wrisley DM, Marchetti GF, Kuharsky DK, Whitney SL. Reliability, internal consistency, and validity of data obtained with the functional gait assessment. Phys Ther. 2004 Oct;84(10):906-18. PubMed 15449976 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Jul 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2014
First posted
Apr 16, 2014
Start
May 2016
Primary completionActual
Jul 28, 2017
CompletionActual
Jul 28, 2017
Results first posted
Oct 30, 2018
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02115633
Lead sponsor
RxFunction Inc.
Responsible party
Sponsor
First posted
Apr 16, 2014
Start date
May 2016
Primary completion
Jul 28, 2017
Completion
Jul 28, 2017
Results posted
Oct 30, 2018
Last update
Oct 30, 2018

Study contacts

Sara Koehler, PhD
principal investigator · Minneapolis VA

Oversight

Data monitoring committee
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion